欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Gene Therapy
The Gene Editing Technology Innovation Platform
Hematopoietic Stem Cell Platform

Gene Editing Technology Innovation Platform

Gene Editing Technology Innovation Platform

The Gene Editing Technology Innovation Platform (CRISTARS®) is dedicated to developing international leading gene editing tools, obtaining core technologies with independent intellectual property rights, and paving the important foundation for gene editing technology translation. The platform is based on the combination of different single-stranded DNA deaminase structural domains and Cas9 nickase to develop a new generation of DNA base editing tools for broader and more accurate gene editing. The platform has successfully created the world-leading dual base editor and the ultra-high activity cytidine single-base editor (hyper CBE, HyCBE), which can efficiently convert two bases, improve editing activity and broaden the target range. The research results have been published in high-impact peer-review journals such as Nature Biotechnology, Nature Cell Biology, and Cell Research.

World's first successful application of CRISPR/Cas9 for mammalian gene editing

Gene editing is a technology to modify genes with precise modifications, which can be achieved with high efficiency and specificity for specific genomic DNA (or RNA), just as freely and accurately as editing text. In August 2013, a team of Bioraylab scientists published in the prestigious international journal Nature Biotechnology (IF≈43.11) the description of The CRISPR/Cas9 system was successfully used to edit genes in mice and rats. In the years since, Bioraylab scientists have continued to improve the gene editing system, applying it to a variety of applications including gene therapy, cell therapy and humanized animals.

The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 亚洲男人的天堂在线v | 18禁无码无遮挡在线播 | 国产精品乱人一区二区三区 | 日韩av无码专区国产乱码网站 | 波多野结衣av无码 | 久久发布 | 日韩精品久久久久久不卡 | 91自产拍在线观看精品 | 亚洲成熟女同—区二区三区 | 海量高清电影在线点播随时随地 | 国产福利姬视频导航入口 | 免费的成年私人影院网站 | 你的专业电子邮局 | 黄色视频免费看高清版 | 国产精品乱码一区二区三区视频 | 国产91区精品福利在线社区 | 色欧美与xxxxx| 国产精品吹潮在线观看中文 | 国产精品后入内射日本在线观看 | 国产精品今日更新国产主播 | 国产精品人成在线观看 | 最新最好看的热门电影 | 日韩一区二区三免费高清 | 国产福利不卡一区二区三区 | 无码国产精品中文字幕一级区 | 午夜毛片福利精品国产 | 免费无码国产v片在线观看视色 | 日本韩国亚洲综合日韩欧美国产 | 国产精品内射婷婷 | 97人人澡人人爽人人爱 | 日韩免费 | 明星国产欧美日韩在线观看 | 亚洲国产综合在线观看不卡 | 91免费看片 | 在线看吧 | 亚洲高清国产一线 | 2025国产| 国产欧美日韩在线 | 午夜中文字幕日韩精品久久 | 国产成本人片无码免费2025 | 国产精品福利在线观看秒播 |